Cebulla, Nadine http://orcid.org/0000-0002-2376-2281
Schirmer, Daniel
Runau, Eva
Flamm, Leon
Gommersbach, Sonja
Stengel, Helena
Zhou, Xiang
Einsele, Hermann
Reinhold, Ann-Kristin
Rogalla von Bieberstein, Bruno
Zeller, Daniel
Rittner, Heike
Kortüm, K. Martin
Sommer, Claudia
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (DFG So 328/15-1, DFG KO 4604/2-1)
Universitätsklinikum Würzburg
Article History
Received: 16 December 2022
Revised: 7 February 2023
Accepted: 10 February 2023
First Online: 18 February 2023
Declarations
:
: CS is Deputy Editor of the “European Journal of Neurology”, Associate Editor of “PlosOne”, “Neurology Research and Practice” and “Fortschritte der Neurologie und Psychiatrie”. HR is Section Editor for “Pain Reports”. DZ is member of the Editorial Board of “Klinische Neurophysiologie” and Review Editor at “Frontiers in Neurology”. CS has been a consultant for Merz, Omega, Ipsen and Bayer and has given educational talks for Amicus, GSK and Pfizer. DZ received compensation for participation on an advisory board of Biogen, as well as for consultancy work from Novartis. CS is immediate Past President of the International Association for the Study of Pain, Past President of Deutsche Schmerzgesellschaft and Board Member of the Peripheral Nerve Society. The other authors have no competing interests to declare that are relevant to the content of this article.
: This study has been approved by the Ethics Committee of the Medical Faculty of the University of Würzburg (# 98/20). After oral and written information, discussion, and a reflection period of at least 24 h, patients who agreed to participate signed the consent form and were thus included in the study. Controls for NfL detection in the serum were healthy volunteers without pain or other known neurological conditions (Ethics approval # 242/17).